RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
RIGEL PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$46.72+0.75 (+1.63%)
Close on Oct 19, 2026
- Market cap
- $914.31M
- P/E (TTM)
- 2.9
- Dividend yield
- –
Rigel Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Rigel Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $872.72M | $197.05M |
| Enterprise Value | $777.34M | $106.56M |
| PE Ratio | 2.91 | 20.52 |
| PS Ratio | 3.15 | 3.93 |
| PB Ratio | 2.05 | 2.14 |
| P/TBV Ratio | 2.63 | 2.46 |
| P/OCF Ratio | 10.99 | 13.78 |
Enterprise value
| Measure | Rigel Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 2.81 | 2.69 |
| EV / EBITDA | 8.67 | 14.86 |
| EV / EBIT | 8.93 | 19.00 |
Income (trailing twelve months)
| Measure | Rigel Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $276.79M | $57.94M |
| Gross Profit | $252.95M | $90.47M |
| Operating Income | $87.05M | -$21.44M |
| Pretax Income | $85.58M | -$14.45M |
| Net Income | $321.91M | -$22.46M |
| EBITDA | $89.70M | -$16.91M |
| EPS (Diluted) | $16.04 | -$0.83 |
Margins
| Measure | Rigel Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 91.4% | 52.3% |
| Operating Margin | 31.5% | -44.5% |
| Pretax Margin | 30.9% | -13.0% |
| Profit Margin | 116.3% | -39.2% |
| EBITDA Margin | 32.4% | -31.3% |
Returns
| Measure | Rigel Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | 126.9% | -53.1% |
| Return on Assets (ROA) | 88.5% | -41.0% |
| Return on Invested Capital (ROIC) | 57.4% | -32.0% |
| Return on Capital Employed (ROCE) | 20.5% | -37.8% |
Growth
| Measure | Rigel Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 3.31% | 6.01% |
| Net Income Growth (YoY) | 229.1% | -37.7% |
| EPS Growth (YoY) | 196.5% | -29.2% |
| Revenue Growth (3Y CAGR) | 34.8% | 2.25% |
| Revenue Growth (5Y CAGR) | 22.1% | 6.42% |
Balance sheet
| Measure | Rigel Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $95.39M | $62.42M |
| Net Cash (Debt) | $95.39M | $15.68M |
| Net Cash Per Share | $5.11 | $0.65 |
| Equity (Book Value) | $425.42M | $48.79M |
| Book Value Per Share | $22.77 | $1.36 |
| Tangible Book Value | $331.54M | $23.06M |
| Working Capital | $89.94M | $75.77M |
Financial position
| Measure | Rigel Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 1.94 | 3.30 |
| Quick Ratio | 1.58 | 2.39 |
| Interest Coverage | 15.00 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Rigel Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | $79.39M | -$12.35M |
Efficiency
| Measure | Rigel Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.76 | 0.38 |
| Inventory Turnover | 1.92 | 2.67 |
| Revenue Per Employee | $1.88M | $398.96K |
| Profits Per Employee | $2.19M | -$732.08K |
| Employee Count | 147 | 73 |
Dividends and yields
| Measure | Rigel Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | 36.9% | -21.2% |
Shares
| Measure | Rigel Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 18,679,900 | 59,128,900 |
| Shares Change (YoY) | 9.32% | 11.1% |
| Float | 18,067,600 | 48,744,500 |
| Shares Held by Insiders | 3.28% | 11.8% |
| Shares Held by Institutions | 87.7% | 59.4% |
Taxes
| Measure | Rigel Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | -$236.33M | $91.50K |
| Effective Tax Rate | -276.2% | 20.6% |
Scores
| Measure | Rigel Pharmaceuticals | Industry median |
|---|---|---|
| Graham Number | $90.66 | $17.36 |
| Graham Upside | 94.0% | -45.5% |
| Altman Z-Score | 4.09 | 0.10 |
| Piotroski F-Score | 7 | 4 |
| Beneish M-Score | 1.55 | -2.62 |
Calculated by StockData from Rigel Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.